Qing-qing Cai, MD, Sun Yat-Sen University Cancer Center, Guangzhou, China, discusses new strategies in treating extranodal natural killer/T-cell lymphoma (ENKTL). Frequently used treatment regimens include SMILE (etoposide, ifosfamide, methotrexate, and dexamethasone) and AspaMetDex (L-asparaginase, methotrexate and dexamethasone). P-GemOx (pegaspargase, gemcitabine and oxaliplatin) is an alternative regimen that results in comparable patients outcomes to AspaMetDex and has shown to be efficacious and safe in combination with sintilimab in a Phase II clinical trial (NCT04127227). Multiple new drugs such as mitoxantrone and CS1001, an anti-PD-L1 monoclonal antibody, have additionally shown to be effective in patients with relapsed/refractory ENKTL. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).